晚期非小细胞肺癌患者化疗前后T细胞亚群临床观察

Clinical observation in T cell subsets in patients with advanced non-small ceall cell lung cancer before and after chemotherapy

目的检测晚期非小细胞肺癌(NSCLC)患者化疗前后T细胞亚群(CD3+、CD3+CD4+、CD3+CD8+、CD4/CD8)的变化,观察细胞免疫状态并探讨免疫治疗的意义。方法对25例晚期NSCLC患者化疗前后检测外周血T细胞亚群,并进行分析。结果 25例化疗前与1,2个周期化疗后对照比较差异均无统计学意义。化疗有效组12例,化疗后免疫功能有升高趋势,但无统计学差异;化疗无效组13例,与化疗前T细胞亚群比较无统计学差异。结论晚期NSCLC患者免疫功能可能降低,但化疗无论有无疗效,细胞免疫功能无明显抑制,提示化疗过程中免疫治疗并非必要。

Objective To detect the changes of T cell subsets（CD3＋、CD3＋CD4＋、CD3＋CD8＋、CD4/CD8）before and after chemotherapy in patients with advanced NSCLC, and observe the changes of the immune status of patients before and after chemotherapy, and explore the significance with a timely and reasonable immunotherapy in patients. Methods Choose 25 patients with advanced NSCLC and observed the changes of the T cell subsets in patients before and after chemotherapy. Results Comparing the ratio of CD3＋、CD3＋CD4＋、CD3＋CD8＋、CD4＋/CD8＋between 25 patients after chemotherapy , the difference has not statistically significant, P＆gt;0.05; Comparing the T cell subsets before chemotherapy respectively with after the first and second chemotherapy , P＆gt;0.05; After two period chemotherapy, the valid group has 12 patients,the ratios of CD3＋、CD3＋CD4＋、CD4＋/CD8＋ are rising, but P＆gt;0.05; Invalid Group has 13 patients, the difference has not too. Conclusion the immune function of patients with advanced NSCLC after chemotherapy or without treatment,not significantly inhibit cellular immune function of patients with advanced NSCLC chemotherapy immune therapy is not necessary in the process.